| 1 |
35223527 | The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. | 2022 |
1 |
| 2 |
33771897 | Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD. | 2021 Jun 15 |
2 |
| 3 |
31821539 | ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. | 2020 Mar 15 |
1 |
| 4 |
32143669 | Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells. | 2020 Mar 6 |
2 |
| 5 |
32482675 | In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis. | 2020 Jul 22 |
1 |
| 6 |
30483795 | Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells. | 2019 Feb |
2 |
| 7 |
30642543 | Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. | 2019 Jan |
1 |
| 8 |
30952700 | An unbiased in vitro screen for activating epidermal growth factor receptor mutations. | 2019 Jun 14 |
2 |
| 9 |
29864158 | DSE promotes aggressive glioma cell phenotypes by enhancing HB-EGF/ErbB signaling. | 2018 |
2 |
| 10 |
29925635 | Afatinib restrains K-RAS-driven lung tumorigenesis. | 2018 Jun 20 |
1 |
| 11 |
30157900 | Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. | 2018 Aug 29 |
8 |
| 12 |
27840411 | Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. | 2017 Feb |
1 |
| 13 |
28288939 | Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. | 2017 Jun |
1 |
| 14 |
28423495 | Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. | 2017 Mar 28 |
1 |
| 15 |
28756224 | Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice. | 2017 Sep 23 |
2 |
| 16 |
29073606 | Inhibitory Effect of Afatinib on Platelet Activation and Apoptosis. | 2017 |
2 |
| 17 |
29110836 | Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. | 2017 Nov |
2 |
| 18 |
26341921 | Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. | 2016 Jan 15 |
5 |
| 19 |
26682573 | Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. | 2016 Jan |
1 |
| 20 |
26826475 | Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. | 2016 Feb 15 |
1 |
| 21 |
27251290 | Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. | 2016 Jun 2 |
3 |
| 22 |
27497236 | Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents. | 2016 Oct |
1 |
| 23 |
27794398 | Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. | 2016 Nov |
6 |
| 24 |
25853020 | A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice. | 2015 |
1 |
| 25 |
26206867 | EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. | 2015 Dec 1 |
1 |
| 26 |
25066021 | Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. | 2014 Oct |
3 |
| 27 |
23153706 | Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. | 2013 Apr |
1 |
| 28 |
23443806 | Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. | 2013 May |
1 |
| 29 |
24386407 | Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. | 2013 |
1 |
| 30 |
22956644 | HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. | 2012 Oct |
1 |
| 31 |
22969147 | Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. | 2012 Nov 15 |
1 |
| 32 |
19759520 | Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. | 2009 Oct |
2 |